Get started
Author

Emmanuel Bouillaud

Observed names: Bouillaud, E., Bouillaud, Emmanuel, E Bouillaud, E. Bouillaud
OpenAlex ID: A5035546311
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
2022 · Brown, David M, Emanuelli, Andrés, et al. · 141
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema
2023 · Charles C. Wykoff, Justus G. Garweg, et al. · American Journal of Ophthalmology · 56
PDF
LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2025 · S.T. Tagawa, O. Sartor, et al. · Annals of Oncology · 50
PDF
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
2013 · Edward M. Wolin, Ke Hu, et al. · Cancer Chemotherapy and Pharmacology · 44
PDF
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study
2012 · H. Dietrich, K. Hu, et al. · European Journal of Endocrinology · 36
Pasireotide (SOM230), a Novel Multireceptor‐Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7‐Day Subcutaneous Infusion in Healthy Male Volunteers
2011 · Stephan Petersenn, Nicole Unger, et al. · The Journal of Clinical Pharmacology · 34
Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia
2014 · Antonio Piga, Silvia Fracchia, et al. · British Journal of Haematology · 30
PDF
An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers
2012 · Magdy Shenouda, Mario Maldonado, et al. · American Journal of Therapeutics · 28
Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
2013 · Jan Peveling-Oberhag, Stefan Zeuzem, et al. · Clinical Therapeutics · 25
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
2012 · Christoph Beglinger, Ke Hu, et al. · Endocrine · 18
Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study
2012 · Stephan Petersenn, Ke Hu, et al. · Clinical Therapeutics · 17
A Phase I Study Evaluating the Effect of Everolimus on the Pharmacokinetics of Midazolam in Healthy Subjects
2013 · Shweta Urva, Emmanuel Bouillaud, et al. · The Journal of Clinical Pharmacology · 14
Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)
2021 · Noelia Nebot, Christina S. Won, et al. · Clinical Pharmacology in Drug Development · 13
PDF
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
2026 · Scott T Tagawa, Oliver Sartor, et al. · The Lancet · 12
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers
2015 · Wing Cheung, Karen Thudium, et al. · Clinical Pharmacology Advances and Applications · 10
PDF
Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study
2012 · Yves Horsmans, Ke Hu, et al. · The Journal of Clinical Pharmacology · 9
Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials
2017 · Shinzaburo Noguchi, Nobuo Shinohara, et al. · Oncology · 6
Subgroup analyses by disease volume and de novo /recurrent mHSPC in the PSMAddition study of [ 177 Lu]Lu-PSMA-617.
2026 · Fred Saad, Scott T. Tagawa, et al. · Journal of Clinical Oncology · 2
Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure
2025 · Michael Ip, Varun Chaudhary, et al. · Ophthalmology Retina · 2
HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration
2022 · David M. Brown, Marta Nowik, et al. · Current Eye Research · 2
Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia
2012 · Antonio Piga, Silvia Fracchia, et al. · Blood · 2
Pd23-02 Prostate-specific Antigen Endpoints in the Phase 3 Psmaddition Study of [ 177 Lu]lu-psma-617 ( 177 Lu-psma-617) Combined With Adt and Arpi in Patients With Psma-positive (psma+) Metastatic Hormone-sensitive Prostate Cancer (mhspc)
2026 · Fred Saad, Scott T. Tagawa, et al. · The Journal of Urology · 1
Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC.
2026 · Michael J. Morris, Shilpa Gupta, et al. · Journal of Clinical Oncology · 1
PDF
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
2026 · S Tagawa, O Sartor, et al. · Nuklearmedizin - NuclearMedicine
CO40 Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Brolucizumab 6 Mg vs Aflibercept 2 Mg in the Kestrel and Kite Studies
2022 · F Felizzi, E Bouillaud, et al. · Value in Health
Works count: 33
Citation count: 551
H-index: 13
I10-index: 15
Year
Topic
Type